Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biogen Idec To Cut Jobs In Restructuring
by Michael McCoy
November 8, 2010
| A version of this story appeared in
Volume 88, Issue 45
Biogen Idec has embarked on a restructuring that will eliminate about 650 full-time positions, or 13% of its workforce. The restructuring, the first big move by new CEO George Scangos, will see the firm close a facility in San Diego and two in eastern Massachusetts. The company will focus on neurology, terminating its efforts in cardiovascular medicine and spinning off its oncology assets. Moreover, it will focus on biologics R&D and “substantially reduce” its small-molecule discovery program and process development effort.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X